Walmart U.S. CEO John Furner commented on a perceived shift in food buying patterns among consumers using weight loss drugs like Ozempic, observing a slight reduction in the overall food basket and calorie intake. As these appetite-curbing drugs gain traction, projections suggest that 7% of the U.S. population might use them by 2035. However, a counterpoint by @DisruptorStocks suggests that these GLP-1 drugs are being wrongfully blamed. They highlight that year-over-year volume changes in various food categories are down across the board, not solely due to appetite suppression in a segment of the population.
Source: Forbes & @DisruptorStocks